Physician profile
John David Harris
NPI 1871518860
$5,222.25
in general payments reported to CMS, 2019-2025
44 companies · $849 in 2025
The $849 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $893 · 2021: $709 · 2022: $706 · 2023: $734 · 2024: $782 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,306 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,306.40 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $508.23 | 2021-2025 | |
| Glaxosmithkline, LLC. | $507.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $371.97 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $312.44 | 2019-2025 | |
| Amgen INC. | $305.85 | 2019-2025 | Evenity, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $294.14 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $250.39 | 2019-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $249.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $209.23 | 2020-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.01 | 2019-2023 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $168.42 | 2019-2023 | Seglentis |
| Amarin Pharma, INC. | $166.70 | 2019-2022 | |
| Dexcom, INC. | $141.25 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $113.32 | 2019-2023 | Steglatro, Belsomra |
| Arbor Pharmaceuticals, INC. | $108.71 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.